Risk of Absence of Measles Antibody in Healthcare Personnel and Efficacy of Booster Vaccination
Abstract
:1. Introduction
2. Materials and Methods
2.1. Participants and Exclusion Criteria
2.2. Study Protocol
2.3. Subgroup Analysis
2.4. Statistical Analysis
2.5. Ethics Statement
3. Results
3.1. Baseline Characteristics and mIgG-Ab Seroprevalence
3.2. History of Measles Vaccination
3.3. Serologic Response to MMR Vaccination
3.4. Subgroup Analysis: Population Subject to Catch-Up Vaccination in 2001
3.5. mIgG-Ab Avidity Assay
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Fraser, B. Measles outbreak in the Americas. Lancet 2018, 392, 373. [Google Scholar] [CrossRef]
- Le, N.K.; Mhaskar, R.; Hoare, I.; Espinel, M.; Fernanda Rivadeneira, M.; Malavade, S.; Izurieta, R. Reemergence of Measles in the Americas: The Genotype B3 2011–2012 Outbreak in Ecuador. Vaccines 2017, 5, 15. [Google Scholar] [CrossRef][Green Version]
- Moss, W.J. Measles. Lancet 2017, 390, 2490–2502. [Google Scholar] [CrossRef]
- Choe, Y.J.; Park, Y.J.; Kim, J.W.; Eom, H.E.; Park, O.; Oh, M.D.; Lee, J.K. An Outbreak of Measles in a University in Korea, 2014. J. Korean Med. Sci. 2017, 32, 1876–1878. [Google Scholar] [CrossRef]
- Hens, N.; Abrams, S.; Santermans, E.; Theeten, H.; Goeyvaerts, N.; Lernout, T.; Leuridan, E.; Van Kerckhove, K.; Goossens, H.; Van Damme, P.; et al. Assessing the risk of measles resurgence in a highly vaccinated population: Belgium anno 2013. Eurosurveillance 2015, 20. [Google Scholar] [CrossRef]
- Park, J.W.; Yu, S.N.; Park, E.; Lee, Y.; Park, S.M.; Jeon, M.H. Modified Measles in an Anti-Measles Immunoglobulin G-negative Healthcare Worker who had Received Two Doses of Measles-Containing Vaccine. Infect. Chemother. 2019, 51, 305–309. [Google Scholar] [CrossRef]
- Park, S.H.; Lee, D.H.; Jin, J.Y.; Shin, Y.L.; Shin, M.; Kim, S.S.; Suh, W.S.; Park, J.O.; Hong, Y.H. Measles outbreaks in the Kyeongin area of the Republic of Korea, 2013–2014: A single-center experience in a country of measles elimination. Asian Pac. J. Trop. Med. 2017, 10, 69–74. [Google Scholar] [CrossRef]
- Jung, J.; Kim, S.K.; Kwak, S.H.; Hong, M.J.; Kim, S.H. Seroprevalence of Measles in Healthcare Workers in South Korea. Infect. Chemother. 2019, 51, 58–61. [Google Scholar] [CrossRef]
- Guerra, F.M.; Bolotin, S.; Lim, G.; Heffernan, J.; Deeks, S.L.; Li, Y.; Crowcroft, N.S. The basic reproduction number (R0) of measles: A systematic review. Lancet Infect. Dis. 2017, 17, e420–e428. [Google Scholar] [CrossRef]
- Zhang, Z.; Zhao, Y.; Yang, L.; Lu, C.; Meng, Y.; Guan, X.; An, H.; Zhang, M.; Guo, W.; Shang, B.; et al. Measles Outbreak among Previously Immunized Adult Healthcare Workers, China, 2015. Can. J. Infect. Dis. Med. Microbiol. 2016, 2016, 1742530. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Bester, J.C. Measles and Measles Vaccination: A Review. JAMA Pediatr. 2016, 170, 1209–1215. [Google Scholar] [CrossRef] [PubMed]
- Advisory Committee on Immunization Practices; Centers for Disease Prevention. Immunization of health-care personnel: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2011, 60, 1–45. [Google Scholar]
- Kang, J.H. Review of Measles in Korea: Quarantine and Elimination. Infect. Chemother. 2020, 52, 113–122. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Chang, H.H.; Kim, S.W.; Kwon, K.T.; Kim, H.I.; Kim, M.J.; Ryu, S.Y.; Kim, H.A.; Hur, J.; Kwon, H.H.; Hong, H.L. Preliminary Report of Seroprevalence of Anti-Measles Immunoglobulin G among Healthcare Workers of 6 Teaching Hospitals of Daegu, Korea in 2019. Infect. Chemother. 2019, 51, 54–57. [Google Scholar] [CrossRef] [PubMed]
- Kwak, Y.G.; Song, J.E.; Oh, G.B.; Jeong, I.H.; Cho, C.R.; Kim, N.; Yoo, H.M.; Yoo, G.M.; Lee, M.J.; Kim, B.N. Comparison of the Seroprevalence of Measles Antibodies among Healthcare Workers in Two Korean Hospitals in 2019. Infect. Chemother. 2020, 52, 93–97. [Google Scholar] [CrossRef][Green Version]
- Lebo, E.J.; Kruszon-Moran, D.M.; Marin, M.; Bellini, W.J.; Schmid, S.; Bialek, S.R.; Wallace, G.S.; McLean, H.Q. Seroprevalence of measles, mumps, rubella and varicella antibodies in the United States population, 2009–2010. Open Forum. Infect. Dis. 2015, 2, ofv006. [Google Scholar] [CrossRef]
- Pei, L.; Yang, Y.; Zhao, X.; Zhang, S.; Yuan, L.; Liu, Y.; Yu, Y. Identify the susceptibility profile to measles in the general population: Serological survey of measles antibodies in Shaanxi province, China, in 2016. Vaccine 2017, 35, 7250–7255. [Google Scholar] [CrossRef]
- Boulton, M.L.; Wang, X.; Zhang, Y.; Montgomery, J.P.; Wagner, A.L.; Carlson, B.F.; Ding, Y.; Li, X.; Gillespie, B.; Su, X. A population profile of measles susceptibility in Tianjin, China. Vaccine 2016, 34, 3037–3043. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Kang, H.J.; Han, Y.W.; Kim, S.J.; Kim, Y.J.; Kim, A.R.; Kim, J.A.; Jung, H.D.; Eom, H.E.; Park, O.; Kim, S.S. An increasing, potentially measles-susceptible population over time after vaccination in Korea. Vaccine 2017, 35, 4126–4132. [Google Scholar] [CrossRef]
- Mercader, S.; Garcia, P.; Bellini, W.J. Measles virus IgG avidity assay for use in classification of measles vaccine failure in measles elimination settings. Clin. Vaccine Immunol. 2012, 19, 1810–1817. [Google Scholar] [CrossRef][Green Version]
- Vandermeulen, C.; Mathieu, R.; Geert, L.R.; Pierre, V.D.; Karel, H. Long-term persistence of antibodies after one or two doses of MMR-vaccine. Vaccine 2007, 25, 6672–6676. [Google Scholar] [CrossRef] [PubMed]
- Yang, L.; Grenfell, B.T.; Mina, M.J. Waning immunity and re-emergence of measles and mumps in the vaccine era. Curr. Opin. Virol. 2020, 40, 48–54. [Google Scholar] [CrossRef] [PubMed]
- Kontio, M.; Jokinen, S.; Paunio, M.; Peltola, H.; Davidkin, I. Waning antibody levels and avidity: Implications for MMR vaccine-induced protection. J. Infect. Dis. 2012, 206, 1542–1548. [Google Scholar] [CrossRef]
- Cardemil, C.V.; Dahl, R.M.; James, L.; Wannemuehler, K.; Gary, H.E.; Shah, M.; Marin, M.; Riley, J.; Feikin, D.R.; Patel, M.; et al. Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control. N. Engl. J. Med. 2017, 377, 947–956. [Google Scholar] [CrossRef]
- Antona, D.; Morel, P.; Jacquot, C.; Fonteneau, L.; Dina, J.; Vauloup-Fellous, C.; Gimeno, L.; Degeorges, A.; Gallian, P.; Levy-Bruhl, D. Measles and rubella seroprevalence in a population of young adult blood donors, France 2013. Epidemiol. Infect. 2019, 147, e109. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Diaz-Ortega, J.L.; Ferreira-Guerrero, E.; Cruz-Hervert, L.P.; Delgado-Sanchez, G.; Ferreyra-Reyes, L.; Yanes-Lane, M.; Mongua-Rodriguez, N.; Montero-Campos, R.; Castaneda-Desales, D.; Garcia-Garcia, L. Seroprevalence of measles antibodies and factors associated with susceptibility: A national survey in Mexico using a plaque reduction neutralization test. Sci. Rep. 2020, 10, 17488. [Google Scholar] [CrossRef]
- Emek, M.; Islek, D.; Atasoylu, G.; Ozbek, O.A.; Ceylan, A.; Acikgoz, A.; Tay, Z.; Demiral, Y.; Oktem, M.A.; Unal, B. Association between seroprevalence of measles and various social determinants in the year following a measles outbreak in Turkey. Public Health 2017, 147, 51–58. [Google Scholar] [CrossRef]
- Estofolete, C.F.; Milhim, B.; Franca, C.C.G.; Silva, G.; Augusto, M.T.; Terzian, A.C.B.; Zini, N.; Durigon, E.L.; Oliveira, D.B.L.; Massad, E.; et al. Prevalence of Measles Antibodies in Sao Jose do Rio Preto, Sao Paulo, Brazil: A serological survey model. Sci. Rep. 2020, 10, 5179. [Google Scholar] [CrossRef][Green Version]
- Fu, C.; Xu, J.; Liu, W.; Zhang, W.; Wang, M.; Nie, J.; Rudiger, K. Low measles seropositivity rate among children and young adults: A sero-epidemiological study in southern China in 2008. Vaccine 2010, 28, 8219–8223. [Google Scholar] [CrossRef]
- Khetsuriani, N.; Chitadze, N.; Russell, S.; Ben Mamou, M. Measles and rubella seroprevalence among adults in Georgia in 2015: Helping guide the elimination efforts. Epidemiol. Infect. 2019, 147, e319. [Google Scholar] [CrossRef][Green Version]
- Levine, H.; Zarka, S.; Ankol, O.E.; Rozhavski, V.; Davidovitch, N.; Aboudy, Y.; Balicer, R.D. Seroprevalence of measles, mumps and rubella among young adults, after 20 years of universal 2-dose MMR vaccination in Israel. Hum. Vaccin Immunother. 2015, 11, 1400–1405. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Odemis, I.; Kose, S.; Akbulut, I.; Albayrak, H. Seroprevalence of measles, mumps, rubella, and varicella zoster virus antibodies among healthcare students: Analysis of vaccine efficacy and cost-effectiveness. Rev. Esp. Quimioter. 2019, 32, 525–531. [Google Scholar] [PubMed]
- Smetana, J.; Chlibek, R.; Hanovcova, I.; Sosovickova, R.; Smetanova, L.; Gal, P.; Dite, P. Decreasing Seroprevalence of Measles Antibodies after Vaccination-Possible Gap in Measles Protection in Adults in the Czech Republic. PLoS ONE 2017, 12, e0170257. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Fiebelkorn, A.P.; Coleman, L.A.; Belongia, E.A.; Freeman, S.K.; York, D.; Bi, D.; Kulkarni, A.; Audet, S.; Mercader, S.; McGrew, M.; et al. Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults. J. Infect. Dis. 2016, 213, 1115–1123. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Choe, Y.J.; Eom, H.E.; Cho, S.I. Trend of measles, mumps, and rubella incidence following the measles-rubella catch up vaccination in the Republic of Korea, 2001. J. Med. Virol. 2017, 89, 1528–1531. [Google Scholar] [CrossRef]
- Cha, H.-G.; Ha, E.-H. Subjectivity of Parents in Refusal of Childhood Vaccination: A Q-methodology Approach. Child. Health Nurs. Res. 2013, 19, 216–227. [Google Scholar] [CrossRef]
Variable | mIgG-Ab | p-Value | |
---|---|---|---|
Negative/Equivocal (n = 234) | Positive (n = 2651) | ||
Sex | |||
Male | 32 (13.7%) | 600 (22.6%) | 0.001 * |
Female | 202 (86.3%) | 2051 (77.4%) | |
Age (years) (mean, SD) | 28.1 (±6.6) | 35.5 (±10.3) | <0.001 † |
Occupation | |||
Doctor | 27 (11.5%) | 425 (16.0%) | 0.049 * |
Nurse | 144 (61.5%) | 1394 (52.6%) | |
Other medical personnel | 31 (13.2%) | 369 (13.9%) | |
Non-patient contact | 32 (13.7%) | 463 (17.5%) | |
Number of previously recorded vaccinations | |||
Birth prior to 1985 | |||
Unknown | 38 (95.0%) | 1145 (93.0%) | 0.849 * |
Once | 2 (5.0%) | 81 (6.6%) | |
Twice or more | 0 | 5 (0.4%) | |
Birth during or after 1985 | |||
Unknown | 60 (30.9%) | 199 (14.0%) | <0.001 * |
Once | 122 (62.9%) | 1033 (72.7%) | |
Twice or more | 12 (6.2%) | 188 (13.2%) |
Previous History of Vaccination | mIgG-Ab | Total | p-Value | ||
---|---|---|---|---|---|
Birth Year | Since Last Vaccination | Negative | Positive | ||
Unknown history of vaccination | |||||
<1985 | 38 | 1145 | 1183 | ||
≥1985 | 60 | 199 | 259 | ||
Received single vaccination dose | |||||
<1985 | 0–10 years | 2 (100%) | 80 (98.8%) | 82 | 0.874 * |
Over 11 years | 0 | 1 (1.2%) | 1 | ||
≥1985 | 0–10 years | 6 (4.9%) | 132 (12.8%) | 138 | 0.011 † |
Over 11 years | 116 (95.1%) | 901 (87.2%) | 1017 | ||
Received two or more vaccination doses | |||||
<1985 | 0–10 years | 0 | 5 (100%) | 5 | |
Over 11 years | 0 | 0 | 0 | ||
≥1985 | 0–10 years | 8 (66.7%) | 161 (85.6%) | 169 | 0.078 * |
Over 11 years | 4 (33.3%) | 27 (14.4%) | 31 |
Variable | Negative after 1st Vaccination (n = 20) | Positive Conversion after 1st Vaccination (n = 126) | p-Value |
---|---|---|---|
Male | 4 (20.0%) | 13 (10.3%) | 0.254 * |
Birth year | |||
<1970s | 0 | 0 | 0.728 † |
1971–1980 | 1 (25.0%) | 2 (15.4%) | |
1981–1984 | 0 | 0 | |
1985–1990 | 1 (25.0%) | 4 (30.8%) | |
1991–1994 | 1 (25.0%) | 6 (46.2%) | |
≥1995 | 1 (25.0%) | 1 (7.7%) | |
Female | 16 (80.0%) | 113 (89.7%) | 0.254 * |
Birth year | |||
<1970s | 0 | 2 (1.8%) | 0.692 † |
1971–1980 | 1 (6.3%) | 7 (6.2%) | |
1981–1984 | 1 (6.3%) | 9 (8.0%) | |
1985–1990 | 1 (6.3%) | 11 (9.7%) | |
1991–1994 | 5 (31.3%) | 51 (45.1%) | |
≥1995 | 8 (50.0%) | 33 (29.2%) | |
Previous vaccination history | |||
No history | 13 (65.0%) | 55 (43.7%) | 0.156 † |
Received one dose | 6 (30.0%) | 67 (53.2%) | |
Received ≥ 2 doses | 1 (5.0%) | 4 (3.2%) | |
Length of time between last vaccination and current vaccination | |||
≤10 years | 0 | 6 (8.5%) | 1.000 * |
≥11years | 7 (100%) | 65 (91.5%) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kim, C.-J.; Bae, J.-Y.; Jun, K.-I.; Chung, H.-S.; Kim, A.; Kim, J.; Son, H.-J.; Lee, M.; Choi, H.-J. Risk of Absence of Measles Antibody in Healthcare Personnel and Efficacy of Booster Vaccination. Vaccines 2021, 9, 501. https://doi.org/10.3390/vaccines9050501
Kim C-J, Bae J-Y, Jun K-I, Chung H-S, Kim A, Kim J, Son H-J, Lee M, Choi H-J. Risk of Absence of Measles Antibody in Healthcare Personnel and Efficacy of Booster Vaccination. Vaccines. 2021; 9(5):501. https://doi.org/10.3390/vaccines9050501
Chicago/Turabian StyleKim, Chung-Jong, Ji-Yun Bae, Kang-Il Jun, Hae-Sun Chung, Aeyeon Kim, Jihee Kim, Hee-Jung Son, Miae Lee, and Hee-Jung Choi. 2021. "Risk of Absence of Measles Antibody in Healthcare Personnel and Efficacy of Booster Vaccination" Vaccines 9, no. 5: 501. https://doi.org/10.3390/vaccines9050501